Recently, scientists are categorizing breast cancer on the receptor status and chalking out strategic planning of treatment. Though some medications used in receptor positive cancers have effect on triple negative cancer, still those are not fully responsive.
To find more targeted approach scientists are focusing on it. Now, they have found out that insulin like growth factor receptor (IGF-1R) over expression is associated with less outside spread of breast cancer, i.e. the more is this protein the better is the outcome for triple negative breast cancer. Less IGF-1R is associated with more spread to lymph nodes. High expression levels were also linked to longer survival rates among patients younger than 55 years.
The next step forward is perhaps to learn if triple-negative breast cancer patients benefit from targeting IGF-1R.